Inflammation Development Triggered by Epiregulin Regulates Temporal Expression of Growth Factors

In this study, we investigated the relationship between several growth factors and inflammation development. Serum concentrations of epiregulin, amphiregulin, betacellulin, TGF- a , fibroblast growth factor 2, placental growth factor (PLGF), and tenascin C were increased in rheumatoid arthritis patients. Furthermore, local blockades of these growth factors suppressed the development of cytokine-induced arthritis in mice by inhibiting chemokine and IL-6 expressions. We found that epiregulin expression was early and followed by the induction of other growth factors at different sites of the joints. The same growth factors then regulated the expression of epiregulin at later time points of the arthritis. These growth factors were increased in patients suffering from multiple sclerosis (MS) and also played a role in the development of an MS model, experimental autoimmune encephalomyelitis. The results suggest that the temporal expression of growth factors is involved in the inflammation development seen in several diseases, including rheumatoid arthritis and MS. Therefore, various growth factor pathways might be good therapeutic targets for various inflammatory diseases. The Journal of Immunology , 2015, 194:

[1]  T. Hirano,et al.  Inflammation amplifier, a new paradigm in cancer biology. , 2014, Cancer research.

[2]  S. Miyoshi,et al.  IL-6 amplifier activation in epithelial regions of bronchi after allogeneic lung transplantation. , 2013, International immunology.

[3]  T. Hirano,et al.  Disease-association analysis of an inflammation-related feedback loop. , 2013, Cell reports.

[4]  S. Miyoshi,et al.  IL-6 Amplifier, NF-κB–Triggered Positive Feedback for IL-6 Signaling, in Grafts Is Involved in Allogeneic Rejection Responses , 2012, The Journal of Immunology.

[5]  Timothy S. Blackwell,et al.  Regional Neural Activation Defines a Gateway for Autoreactive T Cells to Cross the Blood-Brain Barrier , 2012, Cell.

[6]  T. Hirano,et al.  Local microbleeding facilitates IL-6– and IL-17–dependent arthritis in the absence of tissue antigen recognition by activated T cells , 2011, The Journal of experimental medicine.

[7]  T. Hirano,et al.  Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[8]  Issa J. Dahabreh,et al.  Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC , 2009, Nature Reviews Clinical Oncology.

[9]  小椋 英樹,et al.  Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction , 2009 .

[10]  Toshio Hirano,et al.  Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.

[11]  T. Blackwell,et al.  Bioluminescence: imaging modality for in vitro and in vivo gene expression. , 2008, Methods in molecular biology.

[12]  Toshio Hirano,et al.  IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. , 2007, International immunology.

[13]  T. Hirano,et al.  Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7–dependent homeostatic proliferation of CD4+ T cells , 2006, The Journal of experimental medicine.

[14]  Tony Hunter,et al.  Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. , 2003, Cancer cell.

[15]  Y. Saeki,et al.  A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.

[16]  T. Hirano,et al.  Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. , 2000, Immunity.

[17]  T. Hirano.  Interleukin 6 and its receptor: ten years later. , 1998, International reviews of immunology.

[18]  R. J. Hocking,et al.  TGFb in the Context of an Inflammatory Cytokine Milieu Supports De Novo Differentiation of IL-17-Producing T Cells , 2022 .